Search Patents
  • Agents that bind to and inhibit human cytochrome P450 2C19
    Patent number: 6908738
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: June 21, 2005
    Assignee: National Institute of Health
    Inventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
  • Agents that bind to and inhibit human cytochrome P450 2C19
    Patent number: 7262018
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.
    Type: Grant
    Filed: September 14, 2004
    Date of Patent: August 28, 2007
    Assignee: National Institutes of Health
    Inventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
  • Agents that bind to and inhibit human cytochrome P450 2C19
    Patent number: 7682800
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: March 23, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
  • Agents that bind to and inhibit human cytochrome P450 1A2
    Patent number: 6335428
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 1A2 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 1A2 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 1A2, and in methods of measuring p450 1A2 levels in individuals relative to p450 1A2 levels in a control population.
    Type: Grant
    Filed: April 8, 1999
    Date of Patent: January 1, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry V. Gelboin, Frank J. Gonzalez, Tian J. Yang
  • Agents that bind to and inhibit human cytochrome P450 2A6
    Patent number: 6323325
    Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2A6 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2A6 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2A6, and in methods of measuring p450 2A6 levels in an individual relative to p450 2A6 levels in a control population.
    Type: Grant
    Filed: April 8, 1999
    Date of Patent: November 27, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry V. Gelboin, Frank J. Gonzalez